Skip to content

Use of prickly pear powder in anemia of long term renal failure patients.

EFFECT OF OPUNTIA ELATIOR MILL.(PRICKLY PEAR) POWDER AS COMPARED TO ERYTHROPOIETIN ON ANAEMIA PROFILE IN NON â?? DIALYSIS PATIENTS OF CHRONIC RENAL FAILURE.

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/12/016593
Enrollment
30
Registered
2018-12-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N182- Chronic kidney disease, stage 2 (mild) Health Condition 2: N183- Chronic kidney disease, stage 3 (moderate) Health Condition 3: N184- Chronic kidney disease, stage 4 (severe)

Interventions

Intervention1: Opuntia elatior Mill. Prickly pear) Capsule: Prickly pear capsule 500 mg three times in a day with water. Duration: 56 days Route of Administration - Orally Control Intervention1: ERYTH

Sponsors

J S Ayurveda Mahavidyalaya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients having clinical features of chronic renal failure and Haemoglobin level between 5 g/dL to 10 g/dL, raised serum creatinine (1.4 g/dL to 7.0 g/dL), blood urea level. 2. Age 18 to 65 years of both gender and willing to give their consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Patient age below 18 year and above 65 year of either sex. 2. Patients on renal replacement therapy. 3. Patients having thalassemia, sickle cell anaemia, leukemia and aplastic anaemia. 4. Patients with bleeding piles or any other bleeding disorders. 5. Patients associated with carcinoma of any organ, cardiac disease, cirrhosis of liver, acute mental disorders, serious acute organic diseases, serious chronic co-morbidity, hypo or hyper thyroidism. 6. Female patients having any of the - menorrhagia, metrorrhagia, pregnancy and lactation period.

Design outcomes

Primary

MeasureTime frame
Changing in Anemia profile.Timepoint: The outcome will be assessed after 56 days of treatment in comparison to before treatment measures

Secondary

MeasureTime frame
Notify improvement in signs and symptoms of patientsTimepoint: The outcome will be assessed after 56 days of treatment in comparison to before treatment measures

Countries

India

Contacts

Public ContactVd Parashar M Akhani

J S Ayurveda Mahavidyalaya

vdtapan@gmail.com9924304388

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026